Jefferies Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Cuts Target Price to $245
Research Alert: Wst Beats Expectations In Q1, Posting Strong Free Cash Flow
William Blair Maintains West Pharmaceutical Services(WST.US) With Buy Rating
BofA Securities Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Cuts Target Price to $280
BofA Securities Cuts West Pharmaceutical Services Price Target to $280 From $285, Maintains Neutral Rating
Evercore Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Maintains Target Price $275
UBS Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Maintains Target Price $285
West Pharma Initiated at Outperform by Evercore ISI Group
West Pharmaceutical Servs Analyst Ratings
Evercore Initiates West Pharmaceutical Services(WST.US) With Buy Rating, Announces Target Price $275
DBS Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Announces Target Price $370
Strong Market Position and Growth Potential Drive Buy Rating for West Pharmaceutical Services
UBS Upgrades West Pharmaceutical Services(WST.US) to Buy Rating, Cuts Target Price to $285
West Pharma Is Maintained at Overweight by Keybanc
West Pharma Price Target Cut to $325.00/Share From $470.00 by Keybanc
West Pharmaceutical Servs Analyst Ratings
Citigroup Adjusts Price Target on West Pharmaceutical Services to $300 From $400
BofA Securities Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Cuts Target Price to $285
Deutsche Bank Upgrades West Pharmaceutical Services(WST.US) to Buy Rating, Cuts Target Price to $250
KeyBanc Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Cuts Target Price to $325